



ASX ANNOUNCEMENT

6 March 2019

CardieX and Major Global Pharma Company Bayer AG Expand Contract for Supply of SphygmoCor® Systems, Data Management, and Clinical Support Services for Multinational Trial for Heart Failure Treatment

Highlights

- CardieX group company AtCor Medical to extend and expand contract with major international pharmaceutical company Bayer AG initially by approximately AUD\$494,000 an increase of 46%.
- Contract is to supply SphygmoCor® systems, data management and clinical trial support services in a multinational clinical study that assesses the treatment of heart failure.
- Expansion of supply contract is a result of an increase in the number of SphygmoCor® systems being utilised, in combination with an increase in data management services required.
- The clinical study will be conducted across 10 countries throughout Europe, and adds greater than 20 study sites, bringing the total number of unique trial sites to more than 70.
- Trial is one of a number of existing clinical trial agreements in which CardieX's SphygmoCor® devices and systems are being utilised in multinational studies for heart failure treatment. The SphygmoCor® unique non-invasive technology provides an innovative market leading integrated tool for assessment of central blood pressure and arterial stiffness, parameters essential to investigate novel drug effects.
- Cost of heart failure to the US amounts to US\$30,000 billion annually with over 5.7 million people affected.
- Contract expansion with Bayer AG further validates CardieX's ability to meet needs of multinational healthcare and pharma companies and highlights its unique market-leading SphygmoCor® technology
- The Phase II trial, originally expected to run for 24 months is expected to open a larger significant opportunity for the Company as the trial progresses.

CardieX Limited (ASX: CDX) (CardieX, the Company) is pleased to announce the extension and expansion of a significant contract previously awarded to its AtCor Medical ("AtCor") subsidiary (ASX Announcement Dec 15, 2017), by major international pharmaceutical company Bayer AG, for a Phase 2a multinational clinical study for patients with congestive heart failure. The original contract included

For personal use only



supply of Atcor's patented SphygmoCor® cardiovascular monitoring systems and data management services for trial sites across Europe.

The expansion of the supply contract is a direct result of an increase in the number of SphygmoCor® systems being utilised, in combination with an increase in data management services required. The information provided through Atcor's SphygmoCor® assessments is especially beneficial in heart failure drug development where the challenges of bringing a novel therapy to the market are well documented.

The extension and expansion of the existing contract with Atcor is likely to see the trial extend beyond the initially planned 18-24 months. The clinical study will be conducted across 10 countries throughout Europe and will require a significant increase in the supply of systems and services through the inclusion of 20 new trials sites, bringing the total number of unique trial sites to more than 70. The Phase 2a trial will be a major study for Bayer AG and the ongoing success is expected to provide a further commercial opportunity for CardieX going forward.

Of significance, AtCor's SphygmoCor® systems are currently being used in all 20 hospitals on the U.S. News Best Hospitals 2017-2018 Honor Roll and have been leveraged by world-leading pharmaceutical companies across the globe to investigate the effects of novel drugs on heart-vascular interactions.

CardieX CEO, Craig Cooper commented, *"It's very significant and satisfying for all of the team and stakeholders at CardieX, that an international multinational pharmaceutical company such as Bayer AG has taken such a strong interest in our unique core technology and clinical trial support services. The expanded contract serves to not only strengthen our product and service value, but also validate the outstanding capability supplied by our Atcor Medical subsidiary."*

For more information please contact:

Chief Executive Officer
Craig Cooper
ccooper@cardiex.com

NWR Communications
Peter Taylor and Anne Leslie
peter@nwrcommunications.com.au
anne@nwrcommunications.com.au
Ph: +61 490 889 419

About CardieX

CardieX Limited is a global health technology company that develops digital and device based solutions for large-scale population health disorders. The Company's XCEL device is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related cardiovascular disorders. CardieX also has a joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating CardieX technology. In November 2018 CardieX entered into an agreement with telehealth services provider, inHealth Medical Services, Inc, allowing CardieX to acquire up to 50.5% of inHealth by way of a convertible note.

For personal use only